Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | ATRX |
Variant | loss |
Impact List | unknown |
Protein Effect | loss of function |
Gene Variant Descriptions | ATRX loss indicates loss of the ATRX gene, mRNA, and protein. |
Associated Drug Resistance | |
Category Variants Paths |
ATRX mutant ATRX inact mut ATRX loss |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATRX loss IDH1 mut | high grade glioma | predicted - sensitive | Gemcitabine + Radiotherapy | Phase I | Actionable | In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339). | 26853339 |
ATRX loss IDH1 mut | malignant astrocytoma | not applicable | N/A | Guideline | Diagnostic | ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org). | detail... |
ATRX loss IDH2 mut | malignant astrocytoma | not applicable | N/A | Guideline | Diagnostic | ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org). | detail... |
ATRX loss IDH1 R132H | high grade glioma | predicted - sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Talzenna (talazoparib) treatment inhibited viability of immortalized astrocytes expressing IDH1 R132H with loss of ATRX in culture (PMID: 34118569). | 34118569 |
ATRX loss IDH1 R132H | high grade glioma | predicted - sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment inhibited viability of immortalized astrocytes expressing IDH1 R132H with loss of ATRX in culture (PMID: 34118569). | 34118569 |